Figure 7.

CXCL10 has a negative effect on myelination. A–E, Myelinating cultures were plated onto PLL-As (A–C) or TnC-As (D, E) and left untreated (A, D), or treated with CXCL10 neutralizing antibody (2 μg/ml, C, E). F, Treatment of TnC-As cultures with CXCL10 neutralizing antibody led to an increase in myelination compared with untreated cultures. Myelinating cultures plated on PLL-As also received 10 ng/ml CXCL10 on day 12 and onward (B, F), which resulted in a reduction in myelination (*p < 0.05). G, Purified OPCs were double-immunolabeled with the O4 antibody and anti-MBP, in addition to A2B5 and anti-MOG, to assess differentiation after CXCL10 treatment for 7 d, followed by staining on day 8 (n = 4). No differences in the percentage of differentiated cells were observed with CXCL10 treatment.